The U.S. Department of Health and Human Services should swiftly use its existing statutory authority—including forcing drug patent owners to license their products to others—to lower drug prices, 100 Democratic members of Congress urged HHS Secretary Xavier Becerra late last month.
“High U.S. medicine prices are the result of prescription drug corporations using their monopoly power to hike prices and pad their bottom lines,” the group of senators and representatives said in a June 23 letter to Becerra released on June 28. “Meanwhile, U.S. law forbids direct government negotiations and other restrictions on pharmaceutical pricing.”
The U.S. Department of Health and Human Services should swiftly use its existing statutory authority—including forcing drug patent owners to license their products to others—to lower drug prices, 100 Democratic members of Congress urged HHS Secretary Xavier Becerra late last month.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
